FDA’s Woodcock Prioritizes Trial Networks As Drug Development Solution
This article was originally published in The Pink Sheet Daily
Culture change, not congressional action is needed advance this step toward faster drug development, FDA’s drug leader tells Energy & Commerce Committee.
You may also be interested in...
Efficient development and review is being hindered by the inability to exchange data freely and truly capitalize on the digital age, CDER director says, challenging industry, regulators and others to creatively think about how to move away from legacy, paper-based processes in clinical trials and regulatory submissions.
Called TransCelerate BioPharma, the initiative funded by 10 big drug firms will work to develop uniform clinical data standards and certification for trial sites and investigators, with deliverables expected by mid-2013.
Califf Clears First Senate Hurdle, But FDA Decision On Abortion Pill May Complicate Final Confirmation
Republican opposition to Califf over agency’s recent move to relax its Mifeprex restrictions is ominous since, in order be confirmed as commissioner, he’ll need enough GOP votes to make up for Democratic opposition over his opioid track record and connections to pharma industry.